Increased Cancer Risk in a Large Population-based Cohort of Patients with Primary Biliary Cirrhosis: Follow-up for Up to 36 Years

Overview

Journal Hepatol Int

Publisher Springer

Specialty Gastroenterology

Date 2015 Jul 24

PMID 26202508

Citations 18

Authors

Kirsten Boonstra

Robin Bokelaar

Paul H Stadhouders

Hans A Tuynman

Alexander C Poen

Karin M van Nieuwkerk

Ellen M Witteman

Dorte Hamann

Ben J Witteman

Ulrich Beuers

Cyriel Y Ponsioen

Affiliations

Soon will be listed here.

Abstract

Background And Aims: The natural history of primary biliary cirrhosis (PBC) has so far mainly been studied in tertiary referral centres. The aim of the present investigation was to describe the natural history of PBC in a large population-based cohort in order to identify risk factors for development of malignancies and disease progression.

Methods: Four independent hospital databases were searched in 44 hospitals in a geographically defined area, after which all medical records were evaluated on site. In addition, PBC registries in the three liver transplant centers were checked for missed referrals from the area of interest.

Results: In total, 992 cases fulfilled the inclusion criteria. The median follow-up was 73 months (range 0-434). Mortality was similar to the age- and gender matched population (SMR 1.1; 95 % CI 0.9-1.4). Male gender, smoking, and elevated bilirubin, decreased albumin, and elevated AST at time of diagnosis, were associated with an increased risk for the combined end point PBC-related death or liver transplantation. In total, 133 (13 %) patients developed one or more malignancies (SIR 1.5; 95 % CI 1.1-1.9). There was a ninefold increased risk of developing hepatobiliary malignancies (SIR 9.4; 95 % CI 3.04-21.8), a fivefold increased risk of developing urinary bladder cancer (SIR 5.0; 95 % CI 1.6-11.6), and a 1.8-fold increased risk of developing breast cancer (SIR 1.8; 95 % CI 1.08-2.81).

Conclusion: PBC is associated with an increased risk of hepatobiliary, bladder and breast cancer. Still, survival-under treatment with ursodeoxycholic acid (UDCA)-was comparable to the general population in this population-based study.

Citing Articles

Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent Considerations.

Kim J, Randhawa H, Sands D, Lambe S, Puglia M, Serrano P Bladder Cancer. 2024; 7(3):261-278.

PMID: 38993608 PMC: 11181825. DOI: 10.3233/BLC-211536.

Are Gender Differences Important for Autoimmune Liver Diseases?.

Floreani A, Gabbia D, De Martin S Life (Basel). 2024; 14(4).

PMID: 38672770 PMC: 11050899. DOI: 10.3390/life14040500.

Current Perspectives on the Molecular and Clinical Relationships between Primary Biliary Cholangitis and Hepatocellular Carcinoma.

Floreani A, Gabbia D, De Martin S Int J Mol Sci. 2024; 25(4).

PMID: 38396870 PMC: 10888596. DOI: 10.3390/ijms25042194.

Risk Stratification in Primary Biliary Cholangitis.

Martini F, Balducci D, Mancinelli M, Buzzanca V, Fracchia E, Tarantino G J Clin Med. 2023; 12(17).

PMID: 37685780 PMC: 10488776. DOI: 10.3390/jcm12175713.

Stromal inflammation, fibrosis and cancer: An old intuition with promising potential.

Oey O, Sunjaya A, Khan Y, Redfern A World J Clin Oncol. 2023; 14(7):230-246.

PMID: 37583950 PMC: 10424089. DOI: 10.5306/wjco.v14.i7.230.

References

Krzeski P, Zych W, Kraszewska E, MILEWSKI B, Butruk E, Habior A . Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis?. Hepatology. 1999; 30(4):865-9. DOI: 10.1002/hep.510300415. View

Poupon R, Chretien Y, Poupon R, Ballet F, Calmus Y, DARNIS F . Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?. Lancet. 1987; 1(8537):834-6. DOI: 10.1016/s0140-6736(87)91610-2. View

Kuiper E, Hansen B, Metselaar H, de Man R, Haagsma E, van Hoek B . Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. BMC Gastroenterol. 2010; 10:144. PMC: 3020176. DOI: 10.1186/1471-230X-10-144. View

Murtaugh P, Dickson E, van Dam G, Malinchoc M, Grambsch P, Langworthy A . Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits. Hepatology. 1994; 20(1 Pt 1):126-34. DOI: 10.1016/0270-9139(94)90144-9. View

Kuiper E, Hansen B, Adang R, van Nieuwkerk C, Timmer R, Drenth J . Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur J Gastroenterol Hepatol. 2011; 22(12):1495-502. DOI: 10.1097/MEG.0b013e32834059e7. View

Gershwin M, Selmi C, Worman H, Gold E, Watnik M, Utts J . Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005; 42(5):1194-202. PMC: 3150736. DOI: 10.1002/hep.20907. View

Mendes F, Kim W, Pedersen R, Therneau T, Lindor K . Mortality attributable to cholestatic liver disease in the United States. Hepatology. 2008; 47(4):1241-7. DOI: 10.1002/hep.22178. View

Liang Y, Yang Z, Zhong R . Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology. 2012; 56(4):1409-17. DOI: 10.1002/hep.25788. View

Christensen E, Altman D, Neuberger J, De Stavola B, Tygstrup N, Williams R . Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups. Gastroenterology. 1993; 105(6):1865-76. DOI: 10.1016/0016-5085(93)91086-w. View

10.

Poupon R, Bonnand A, Chretien Y, Poupon R . Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology. 1999; 29(6):1668-71. DOI: 10.1002/hep.510290603. View

11.

Metcalf J, James O . The geoepidemiology of primary biliary cirrhosis. Semin Liver Dis. 1997; 17(1):13-22. DOI: 10.1055/s-2007-1007179. View

12.

Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C . Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008; 48(3):871-7. DOI: 10.1002/hep.22428. View

13.

. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51(2):237-67. DOI: 10.1016/j.jhep.2009.04.009. View

14.

Letasiova S, Medveova A, Sovcikova A, Dusinska M, Volkovova K, Mosoiu C . Bladder cancer, a review of the environmental risk factors. Environ Health. 2012; 11 Suppl 1:S11. PMC: 3388449. DOI: 10.1186/1476-069X-11-S1-S11. View

15.

Dickson E, Grambsch P, Fleming T, Fisher L, Langworthy A . Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 1989; 10(1):1-7. DOI: 10.1002/hep.1840100102. View

16.

Roll J, Boyer J, Barry D, KLATSKIN G . The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med. 1983; 308(1):1-7. DOI: 10.1056/NEJM198301063080101. View

17.

Bismuth H, Castaing D, Ericzon B, Otte J, Rolles K, Ringe B . Hepatic transplantation in Europe. First Report of the European Liver Transplant Registry. Lancet. 1987; 2(8560):674-6. DOI: 10.1016/s0140-6736(87)92453-6. View

18.

Floreani A, Baragiotta A, Baldo V, Menegon T, Farinati F, Naccarato R . Hepatic and extrahepatic malignancies in primary biliary cirrhosis. Hepatology. 1999; 29(5):1425-8. DOI: 10.1002/hep.510290501. View

19.

Mahl T, Shockcor W, Boyer J . Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol. 1994; 20(6):707-13. DOI: 10.1016/s0168-8278(05)80139-4. View

20.

Ter Borg P, Schalm S, Hansen B, van Buuren H . Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol. 2006; 101(9):2044-50. DOI: 10.1111/j.1572-0241.2006.00699.x. View